This review of patients undergoing adrenalectomy for synchronous or metachronous metastases of the adrenal gland from non-small cell lung cancer concluded that overall survival was shorter in patients with synchronous metastases. The conclusions appeared to reflect the results of the review, but their reliability may be limited by the paucity of information on review methods and included studies.
Study selection
Studies that compared survival outcomes for at least four patients undergoing adrenalectomy for pathologically confirmed synchronous and metachronous metastases from non-small cell lung cancer to the adrenal gland and surgical resection for the primary cancer were eligible for inclusion. Patients with metastasis to other organ sites were excluded, except for those who had undergone resection or definitive radiation of solitary brain metastases. Studies were excluded if the inclusion criteria could not be verified or did not specify the time interval from adrenalectomy until the last follow-up or death.
Synchronous metastasis was defined as a disease-free interval of six months or less. Disease-free interval was defined as the time interval between the date of primary lung cancer resection and the confirmed diagnosis of adrenal metastasis.
Patients in the synchronous metastasis group had a median age of 54 years (range 40 to 63); two thirds were male. The median disease-free interval in this group was 0 months (range 0 to 6 months), the median diameter of metastases was 53cm (range 8 to 150sm), and none of the patients for whom the data were reported had synchronous brain metastasis.
Patients included in the metachronous metastasis group had a median age of 68 years (range 44 to 78); most were male. Their median disease-free interval was 12 months (range 7 to 38 months), the median diameter of metastases 71cm (range 15 to 150cm), and two patients had synchronous brain metastasis. No patients were symptomatic from adrenal metastases.
The authors did not state how the reviewers made decisions on the selection of primary studies.
Assessment of study quality
The reviewers did not state that validity was assessed.
Data extraction
If studies reported results of adrenalectomy for metastases from several cancer sites, only non-small cell lung cancer cases were included. If patients had undergone multiple adrenalectomies, the disease-free interval was calculated from the diagnosis of the first adrenal metastasis. The outcome for the first adrenalectomy was extracted.
The authors did not state how data were extracted for the review.
Methods of synthesis
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Survival was calculated from the time of adrenalectomy to the last follow-up or death. Potential differences in survival were tested using log-rank and generalized Wilcoxon tests. Length of stay and estimated blood loss volume were compared using the exact Wilcoxon rank sum test. P values of 0.05 or below were considered statistically significant.
Results of the review
Ten publications were included in the review, with 114 participants; 42% had synchronous metastases and 58% had metachronous metastases. At the time of reporting, 101 patients had died. Only three included studies reported the outcomes of adrenalectomy exclusively in non-small cell lung cancer patients. In the other seven studies, the eligible patients comprised a subset of those in the reports. One of these studies only reported data from people with metachronous metastasis.
The survival rate at one year was 45% for synchronous tumours and 80% for metachronous tumours; the survival rate at two years was 30% for synchronous tumours and 52% for metachronous tumours; the survival rate at five years was 26% for synchronous tumours and 25% for metachronous tumours. The median overall survival was significantly shorter for patients with synchronous metastasis (median 12 months, 95% confidence interval [95% CI] 10 to 17 months) compared with those with metachronous metastasis (median 31 months, 95% CI 18 to 38 months) using the generalized Wilcoxon (P=0.02) but not the log-rank test (P=0.14).
There was no significant difference in the median disease-free survival (five studies; n=72 patients) for synchronous tumours (9 months, 95% CI 7 to 36 months) or metachronous tumours (11 months, 95% CI 8 to 19 months; Wilcoxon P=0.32; log-rank P 0 .79).
There was no significant difference between groups in estimated blood loss (synchronous group median 175mL; metachronous group 200 m; P=0.30) and length of hospital stay (median five days for both groups; P=0.47). Surgical complications from adrenalectomy were infrequent across both groups.
